id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2011-0005,FDA,FDA-2022-E-2011,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:16Z,,0,0,0900006486365699
FDA-2022-E-2010-0005,FDA,FDA-2022-E-2010,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:02Z,,0,0,0900006486365697
FDA-2022-E-2014-0005,FDA,FDA-2022-E-2014,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:09:57Z,,0,0,0900006486365a1a
FDA-2022-N-2226-0144,FDA,FDA-2022-N-2226,Tab C - FDA Salt Substitutes - NPRM and PRIA - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:42:15Z,,0,0,0900006486366ef1
FDA-2019-N-4750-0041,FDA,FDA-2019-N-4750,Memorandum to FDA DMS on Partially Hydrogenated Oils,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:12Z,,0,0,0900006486365e65
FDA-2019-N-4750-0045,FDA,FDA-2019-N-4750,Tab A - PHOs RIA - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:30Z,,0,0,0900006486365e69
FDA-1997-S-0006-2049,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to Vedistry Pvt Ltd.,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:52Z,,0,0,090000648635f527
FDA-1997-S-0006-2046,FDA,FDA-1997-S-0006,"Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd.",Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:18Z,,0,0,090000648635f0c5
FDA-1997-S-0006-2043,FDA,FDA-1997-S-0006,Courtesy letter and related material from CFSAN to Arbonne International LLC,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:03:49Z,,0,0,090000648635de73
FDA-1997-S-0006-2048,FDA,FDA-1997-S-0006,"Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd.",Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:42Z,,0,0,090000648635f525
FDA-2023-H-5636-0001,FDA,FDA-2023-H-5636,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:34:31Z,,0,0,0900006486361437
FDA-2022-E-2012-0005,FDA,FDA-2022-E-2012,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:29Z,,0,0,090000648636569b
FDA-2019-E-3218-0005,FDA,FDA-2019-E-3218,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:03:25Z,,0,0,0900006486365a16
FDA-2022-E-2013-0005,FDA,FDA-2022-E-2013,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:42Z,,0,0,0900006486365ce2
FDA-2019-N-4750-0048,FDA,FDA-2019-N-4750,Tab B - PHOs PRIA - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:55Z,,0,0,0900006486365e8c
FDA-2019-N-4750-0051,FDA,FDA-2019-N-4750,Tab C - PHOs NPRM - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:23Z,,0,0,0900006486365e91
FDA-2023-H-5667-0001,FDA,FDA-2023-H-5667,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:57:02Z,,0,0,0900006486365657
FDA-1997-S-0006-2044,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to CalmCo LLC,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:03:58Z,,0,0,090000648635d608
FDA-2023-H-5657-0001,FDA,FDA-2023-H-5657,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2024-01-01T05:00:00Z,,2024-01-01T19:24:51Z,,0,0,0900006486366f65
FDA-2023-H-5410-0001,FDA,FDA-2023-H-5410,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2024-01-01T05:00:00Z,,2024-01-01T18:58:41Z,,0,0,0900006486365c81
FDA-2019-N-4750-0046,FDA,FDA-2019-N-4750,Tab B - PHOs DFR - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:46Z,,0,0,0900006486365e6a
FDA-2019-N-4750-0047,FDA,FDA-2019-N-4750,Tab B - PHOs NPRM - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:50Z,,0,0,0900006486365e6b
FDA-2019-N-4750-0050,FDA,FDA-2019-N-4750,Tab C - PHOs DFR - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:18Z,,0,0,0900006486365e8e
FDA-2023-H-5663-0001,FDA,FDA-2023-H-5663,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:52:49Z,,0,0,090000648636564e
FDA-2023-H-5661-0001,FDA,FDA-2023-H-5661,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:39:48Z,,0,0,0900006486366919
FDA-2023-H-5662-0001,FDA,FDA-2023-H-5662,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:41:58Z,,0,0,090000648636692b
FDA-2022-N-2226-0142,FDA,FDA-2022-N-2226,Tab A - FDA Salt Substitutes NPRM and PRIA - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:41:54Z,,0,0,0900006486366edd
FDA-2022-N-2226-0141,FDA,FDA-2022-N-2226,Memorandum to FDA DMS on Salt Substitutes NPRM,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:41:49Z,,0,0,0900006486366eda
FDA-2023-U-5565-0001,FDA,FDA-2023-U-5565,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:07:31Z,,0,0,09000064863612e4
FDA-2023-H-5665-0001,FDA,FDA-2023-H-5665,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:15:06Z,,0,0,0900006486365654
FDA-2023-H-5269-0001,FDA,FDA-2023-H-5269,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:24:00Z,,0,0,0900006486365665
FDA-1997-S-0006-2050,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to CalmCo LLC,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:05:03Z,,0,0,090000648635f529
FDA-2019-E-5256-0005,FDA,FDA-2019-E-5256,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T13:26:57Z,,0,0,090000648636562d
FDA-2019-N-4750-0044,FDA,FDA-2019-N-4750,Tab A - PHOs PRIA - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:25Z,,0,0,0900006486365e68
FDA-2019-N-4750-0049,FDA,FDA-2019-N-4750,Tab B - PHOs RIA - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:01Z,,0,0,0900006486365e8d
FDA-2019-N-4750-0053,FDA,FDA-2019-N-4750,Tab C - PHOs RIA - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:32Z,,0,0,0900006486365e93
FDA-2023-H-5666-0001,FDA,FDA-2023-H-5666,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:46:57Z,,0,0,0900006486364c23
FDA-2023-H-5660-0001,FDA,FDA-2023-H-5660,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:38:09Z,,0,0,09000064863665e4
FDA-2023-H-5672-0001,FDA,FDA-2023-H-5672,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:28:45Z,,0,0,0900006486365662
FDA-2019-E-3017-0005,FDA,FDA-2019-E-3017,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:13:37Z,,0,0,09000064863656c8
FDA-2022-E-2016-0005,FDA,FDA-2022-E-2016,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:10:40Z,,0,0,0900006486365692
FDA-2019-E-3287-0005,FDA,FDA-2019-E-3287,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:14:00Z,,0,0,0900006486365c60
FDA-2023-H-5673-0001,FDA,FDA-2023-H-5673,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T15:05:01Z,,0,0,090000648636568b
FDA-2023-H-5674-0001,FDA,FDA-2023-H-5674,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T15:08:02Z,,0,0,0900006486365c7b
FDA-2023-H-5603-0001,FDA,FDA-2023-H-5603,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:34:53Z,,0,0,0900006486365669
FDA-2019-N-4750-0052,FDA,FDA-2019-N-4750,Tab C - PHOs PRIA - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:27Z,,0,0,0900006486365e92
FDA-2023-H-5177-0001,FDA,FDA-2023-H-5177,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T15:00:37Z,,0,0,09000064862c07f3
FDA-2023-H-5658-0001,FDA,FDA-2023-H-5658,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2024-01-02T05:00:00Z,,2024-01-02T13:25:31Z,,0,0,0900006486366f68
FDA-2022-N-2226-0143,FDA,FDA-2022-N-2226,Tab B - FDA Salt Substitutes NPRM and PRIA - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:42:10Z,,0,0,0900006486366ee2
FDA-1997-S-0006-2045,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to Robinson Pharma,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:07Z,,0,0,090000648635f0c2
FDA-1997-S-0006-2047,FDA,FDA-1997-S-0006,"Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd.",Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:30Z,,0,0,090000648635f521
FDA-2023-H-5664-0001,FDA,FDA-2023-H-5664,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:02:17Z,,0,0,0900006486365651
FDA-2023-H-5670-0001,FDA,FDA-2023-H-5670,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:51:21Z,,0,0,0900006486366931
FDA-2019-N-4750-0042,FDA,FDA-2019-N-4750,Tab A - PHOs DFR - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:16Z,,0,0,0900006486365e66
FDA-2022-E-2009-0005,FDA,FDA-2022-E-2009,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:11:49Z,,0,0,0900006486365c63
FDA-2019-N-4750-0043,FDA,FDA-2019-N-4750,Tab A - PHOs NPRM - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:21Z,,0,0,0900006486365e67
FDA-2023-H-5639-0001,FDA,FDA-2023-H-5639,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:19:51Z,,0,0,090000648635d710
FDA-2023-H-5650-0001,FDA,FDA-2023-H-5650,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T17:50:58Z,,0,0,0900006486361319
FDA-2023-D-5408-0002,FDA,FDA-2023-D-5408,Reformulating Drug Products That Contain Carbomers Manufactured With Benzene; Guidance for Industry - Final Guidance,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2024-11-12T06:24:20Z,,1,0,090000648635c332
FDA-2021-N-0039-0002,FDA,FDA-2021-N-0039,"Electronic Submissions; Update to the Specifications for Preparing and
Submitting Postmarket Individual Case Safety Reports for Vaccines; Technical
Specification",Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2024-11-12T06:21:06Z,2023-28594,1,0,090000648636182b
FDA-2023-H-5647-0001,FDA,FDA-2023-H-5647,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:23:02Z,,0,0,0900006486361407
FDA-2023-H-5648-0001,FDA,FDA-2023-H-5648,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:26:47Z,,0,0,090000648636140a
FDA-2023-H-5643-0001,FDA,FDA-2023-H-5643,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T17:54:09Z,,0,0,09000064863612e1
FDA-2023-H-5645-0001,FDA,FDA-2023-H-5645,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T21:03:53Z,,0,0,0900006486364790
FDA-2023-D-4177-0021,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Revised Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:10:09Z,2023-28595,0,0,090000648636165b
FDA-2023-D-4299-0002,FDA,FDA-2023-D-4299,Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-03-28T03:59:59Z,2024-11-12T06:25:10Z,,1,0,0900006486364261
FDA-2023-H-5637-0001,FDA,FDA-2023-H-5637,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2024-01-01T05:00:00Z,,2024-01-01T19:25:25Z,,0,0,09000064863647c6
FDA-2020-Q-1295-0026,FDA,FDA-2020-Q-1295,Withdrawal request for docket number FDA-2020-Q-1295,Other,Withdrawal,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:40:58Z,,0,0,0900006486364403
FDA-2020-Q-1295-0027,FDA,FDA-2020-Q-1295,FDA response to a withdrawal request for CA and Migraine Final,Other,Acknowledgement Letter/Receipt,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:41:04Z,,0,0,0900006486364405
FDA-2023-D-4177-0022,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Guidance for Industry; Draft Guidance,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-02-27T04:59:59Z,2025-02-04T02:01:06Z,,1,0,09000064863613f7
FDA-2023-H-5644-0001,FDA,FDA-2023-H-5644,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:27:41Z,,0,0,09000064863612e7
FDA-2023-H-5642-0001,FDA,FDA-2023-H-5642,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T17:43:17Z,,0,0,09000064863612d4
FDA-2023-H-5641-0001,FDA,FDA-2023-H-5641,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T17:05:25Z,,0,0,09000064863612d1
FDA-2023-D-4299-0001,FDA,FDA-2023-D-4299,Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T16:34:21Z,2023-28596,0,0,090000648636182c
FDA-2023-H-5646-0001,FDA,FDA-2023-H-5646,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:18:16Z,,0,0,0900006486361404
FDA-2023-H-5640-0001,FDA,FDA-2023-H-5640,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T16:52:22Z,,0,0,09000064863612ce
FDA-2023-D-5408-0001,FDA,FDA-2023-D-5408,Reformulating Drug Products That Contain Carbomers Manufactured With Benzene; Guidance for Industry; Availability,Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T16:02:50Z,2023-28675,0,0,090000648636165e
FDA-2021-V-0192-0007,FDA,FDA-2021-V-0192,Variance Amendment Report from Digital Projection Inc. /Delta Electronics Inc.,Other,Amendment,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T12:46:02Z,,0,0,090000648635cf0d
FDA-2023-H-5413-0001,FDA,FDA-2023-H-5413,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T20:40:47Z,,0,0,09000064863647ec
FDA-2023-H-5638-0001,FDA,FDA-2023-H-5638,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T20:11:28Z,,0,0,09000064863647e6
FDA-2022-E-0931-0005,FDA,FDA-2022-E-0931,Determination of Regulatory Review Period for Purposes of Patent Extension; ZOKINVY,Notice,Determinations,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,2024-06-25T03:59:59Z,2024-06-25T01:00:33Z,2023-28511,0,0,090000648635c4ea
FDA-2023-V-5683-0002,FDA,FDA-2023-V-5683,Acknowledgment Letter from FDA DMS to Billy Stone,Other,Acknowledgement Letter/Receipt,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T16:25:25Z,,0,0,090000648635a86a
FDA-2023-V-5683-0001,FDA,FDA-2023-V-5683,Variance Application from Billy Stone,Other,Application for Variance (VAR),2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T16:22:49Z,,0,0,090000648635a867
FDA-2023-V-5681-0002,FDA,FDA-2023-V-5681,Acknowledgment Letter from FDA DMS to Kasey Lelito,Other,Acknowledgement Letter/Receipt,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T16:12:46Z,,0,0,090000648635a7e7
FDA-2023-H-5602-0001,FDA,FDA-2023-H-5602,Complaint,Other,Complaint,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T18:32:44Z,,0,0,090000648635cbcd
FDA-2023-H-5627-0001,FDA,FDA-2023-H-5627,Complaint,Other,Complaint,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T23:46:41Z,,0,0,090000648635d348
FDA-2023-H-5624-0001,FDA,FDA-2023-H-5624,Complaint,Other,Complaint,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T21:46:25Z,,0,0,090000648635ce56
FDA-2023-V-5190-0003,FDA,FDA-2023-V-5190,Variance Approval Letter from FDA CDRH to ACT Entertainment,Other,Approval for Variance (VRA),2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T13:52:27Z,,0,0,090000648635a687
FDA-2023-V-5680-0002,FDA,FDA-2023-V-5680,Acknowledgment Letter from FDA DMS to Pitchblend Agency Inc.,Other,Acknowledgement Letter/Receipt,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T16:04:59Z,,0,0,090000648635a7ae
FDA-2023-V-5681-0001,FDA,FDA-2023-V-5681,Variance Application from Kasey Lelito,Other,Application for Variance (VAR),2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T16:08:43Z,,0,0,090000648635a9d3
FDA-2009-N-0582-0130,FDA,FDA-2009-N-0582,"Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear,
Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule: Questions and Answers; Guidance for Industry; Small Entity Compliance Guide; Availability",Rule,Final Rule with Request for Comments,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T14:34:36Z,2023-28530,0,0,090000648635c371
FDA-2023-H-5625-0001,FDA,FDA-2023-H-5625,Complaint,Other,Complaint,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T21:34:21Z,,0,0,090000648635d678
FDA-2023-V-5676-0001,FDA,FDA-2023-V-5676,Variance Application from Doug Carmean,Other,Application for Variance (VAR),2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T14:03:42Z,,0,0,090000648635a648
FDA-2023-V-5686-0002,FDA,FDA-2023-V-5686,Acknowledgment Letter from FDA DMS to Will Wall,Other,Acknowledgement Letter/Receipt,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T16:37:19Z,,0,0,090000648635a8bf
FDA-2023-H-5618-0001,FDA,FDA-2023-H-5618,Complaint,Other,Complaint,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T18:07:32Z,,0,0,090000648635c85f
FDA-2023-H-5626-0001,FDA,FDA-2023-H-5626,Complaint,Other,Complaint,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-27T23:44:12Z,,0,0,090000648635d67e
FDA-2023-F-5500-0001,FDA,FDA-2023-F-5500,"Kemin Industries, Inc.; Filing of Food Additive Petition (Animal Use); Chromium Propionate; Correction.",Notice,Correction,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-29T15:38:50Z,2023-28512,0,0,090000648635c3a9
FDA-2023-F-2415-0004,FDA,FDA-2023-F-2415,"Kemin Industries, Inc.; Filing of Food Additive Petition (Animal Use); Chromium Propionate; Correction.",Notice,Correction,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2023-12-29T15:48:26Z,2023-28512,0,0,090000648635d693
FDA-2023-P-5687-0001,FDA,FDA-2023-P-5687,"Citizen Petition from Bionpharma, Inc.",Other,Citizen Petition,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,,2025-03-13T18:36:06Z,,0,0,090000648635b114
FDA-2023-F-5500-0002,FDA,FDA-2023-F-5500,Environmental Assessment Phase 1) Chromium Propionate in Turkey Diets,Supporting & Related Material,Background Material,2023-12-27T05:00:00Z,2023,12,,,2023-12-27T22:00:20Z,,0,0,090000648635d692